Browse HAS2

Summary
SymbolHAS2
Namehyaluronan synthase 2
Aliases HA synthase 2; hyaluronate synthase 2; hyaluronic acid synthase 2
Chromosomal Location8q24.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane Multi-pass membrane protein
Domain PF00535 Glycosyl transferase family 2
Function

Catalyzes the addition of GlcNAc or GlcUA monosaccharides to the nascent hyaluronan polymer. Therefore, it is essential to hyaluronan synthesis a major component of most extracellular matrices that has a structural role in tissues architectures and regulates cell adhesion, migration and differentiation. This is one of the isozymes catalyzing that reaction and it is particularly responsible for the synthesis of high molecular mass hyaluronan. Required for the transition of endocardial cushion cells into mesenchymal cells, a process crucial for heart development. May also play a role in vasculogenesis. High molecular mass hyaluronan also play a role in early contact inhibition a process which stops cell growth when cells come into contact with each other or the extracellular matrix (By similarity).

> Gene Ontology
 
Biological Process GO:0000271 polysaccharide biosynthetic process
GO:0001501 skeletal system development
GO:0001570 vasculogenesis
GO:0001655 urogenital system development
GO:0001667 ameboidal-type cell migration
GO:0001822 kidney development
GO:0001837 epithelial to mesenchymal transition
GO:0003007 heart morphogenesis
GO:0003014 renal system process
GO:0003091 renal water homeostasis
GO:0003097 renal water transport
GO:0005976 polysaccharide metabolic process
GO:0006022 aminoglycan metabolic process
GO:0006023 aminoglycan biosynthetic process
GO:0006024 glycosaminoglycan biosynthetic process
GO:0006109 regulation of carbohydrate metabolic process
GO:0006833 water transport
GO:0007159 leukocyte cell-cell adhesion
GO:0007507 heart development
GO:0010631 epithelial cell migration
GO:0010632 regulation of epithelial cell migration
GO:0010634 positive regulation of epithelial cell migration
GO:0010720 positive regulation of cell development
GO:0010769 regulation of cell morphogenesis involved in differentiation
GO:0010770 positive regulation of cell morphogenesis involved in differentiation
GO:0010810 regulation of cell-substrate adhesion
GO:0010811 positive regulation of cell-substrate adhesion
GO:0010837 regulation of keratinocyte proliferation
GO:0010838 positive regulation of keratinocyte proliferation
GO:0014812 muscle cell migration
GO:0014909 smooth muscle cell migration
GO:0014910 regulation of smooth muscle cell migration
GO:0014911 positive regulation of smooth muscle cell migration
GO:0016051 carbohydrate biosynthetic process
GO:0022407 regulation of cell-cell adhesion
GO:0022409 positive regulation of cell-cell adhesion
GO:0022604 regulation of cell morphogenesis
GO:0030104 water homeostasis
GO:0030198 extracellular matrix organization
GO:0030203 glycosaminoglycan metabolic process
GO:0030212 hyaluronan metabolic process
GO:0030213 hyaluronan biosynthetic process
GO:0030335 positive regulation of cell migration
GO:0031589 cell-substrate adhesion
GO:0032881 regulation of polysaccharide metabolic process
GO:0032885 regulation of polysaccharide biosynthetic process
GO:0033692 cellular polysaccharide biosynthetic process
GO:0034405 response to fluid shear stress
GO:0034446 substrate adhesion-dependent cell spreading
GO:0034612 response to tumor necrosis factor
GO:0034637 cellular carbohydrate biosynthetic process
GO:0035809 regulation of urine volume
GO:0035810 positive regulation of urine volume
GO:0036119 response to platelet-derived growth factor
GO:0036120 cellular response to platelet-derived growth factor stimulus
GO:0036302 atrioventricular canal development
GO:0040017 positive regulation of locomotion
GO:0042044 fluid transport
GO:0042698 ovulation cycle
GO:0043062 extracellular structure organization
GO:0043255 regulation of carbohydrate biosynthetic process
GO:0043616 keratinocyte proliferation
GO:0044262 cellular carbohydrate metabolic process
GO:0044264 cellular polysaccharide metabolic process
GO:0044723 single-organism carbohydrate metabolic process
GO:0044849 estrous cycle
GO:0045226 extracellular polysaccharide biosynthetic process
GO:0045785 positive regulation of cell adhesion
GO:0045913 positive regulation of carbohydrate metabolic process
GO:0046379 extracellular polysaccharide metabolic process
GO:0048511 rhythmic process
GO:0048514 blood vessel morphogenesis
GO:0048705 skeletal system morphogenesis
GO:0048762 mesenchymal cell differentiation
GO:0048871 multicellular organismal homeostasis
GO:0050673 epithelial cell proliferation
GO:0050678 regulation of epithelial cell proliferation
GO:0050679 positive regulation of epithelial cell proliferation
GO:0050878 regulation of body fluid levels
GO:0050891 multicellular organismal water homeostasis
GO:0051272 positive regulation of cellular component movement
GO:0051546 keratinocyte migration
GO:0051547 regulation of keratinocyte migration
GO:0051549 positive regulation of keratinocyte migration
GO:0060317 cardiac epithelial to mesenchymal transition
GO:0060348 bone development
GO:0060349 bone morphogenesis
GO:0060485 mesenchyme development
GO:0070293 renal absorption
GO:0070295 renal water absorption
GO:0070486 leukocyte aggregation
GO:0070487 monocyte aggregation
GO:0070555 response to interleukin-1
GO:0071347 cellular response to interleukin-1
GO:0071356 cellular response to tumor necrosis factor
GO:0071498 cellular response to fluid shear stress
GO:0072001 renal system development
GO:0085029 extracellular matrix assembly
GO:0090130 tissue migration
GO:0090132 epithelium migration
GO:0090500 endocardial cushion to mesenchymal transition
GO:1900024 regulation of substrate adhesion-dependent cell spreading
GO:1900026 positive regulation of substrate adhesion-dependent cell spreading
GO:1900125 regulation of hyaluronan biosynthetic process
GO:1900127 positive regulation of hyaluronan biosynthetic process
GO:1900623 regulation of monocyte aggregation
GO:1900625 positive regulation of monocyte aggregation
GO:1903037 regulation of leukocyte cell-cell adhesion
GO:1903039 positive regulation of leukocyte cell-cell adhesion
GO:1903510 mucopolysaccharide metabolic process
GO:2000147 positive regulation of cell motility
Molecular Function GO:0008194 UDP-glycosyltransferase activity
GO:0016757 transferase activity, transferring glycosyl groups
GO:0016758 transferase activity, transferring hexosyl groups
GO:0050501 hyaluronan synthase activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1630316: Glycosaminoglycan metabolism
R-HSA-2142850: Hyaluronan biosynthesis and export
R-HSA-2142845: Hyaluronan metabolism
R-HSA-1430728: Metabolism
R-HSA-71387: Metabolism of carbohydrates
Summary
SymbolHAS2
Namehyaluronan synthase 2
Aliases HA synthase 2; hyaluronate synthase 2; hyaluronic acid synthase 2
Chromosomal Location8q24.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between HAS2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolHAS2
Namehyaluronan synthase 2
Aliases HA synthase 2; hyaluronate synthase 2; hyaluronic acid synthase 2
Chromosomal Location8q24.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of HAS2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolHAS2
Namehyaluronan synthase 2
Aliases HA synthase 2; hyaluronate synthase 2; hyaluronic acid synthase 2
Chromosomal Location8q24.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of HAS2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.9680.0638
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.6480.133
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.4890.657
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.9480.0263
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.3960.314
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.3810.828
729033130MelanomaallAnti-PD-1 (nivolumab) 26231.1030.142
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.5180.341
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.8290.6
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.7470.217
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.6480.0298
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.540.03
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of HAS2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382703.7-3.70.415
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221307.7-7.70.371
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolHAS2
Namehyaluronan synthase 2
Aliases HA synthase 2; hyaluronate synthase 2; hyaluronic acid synthase 2
Chromosomal Location8q24.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of HAS2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolHAS2
Namehyaluronan synthase 2
Aliases HA synthase 2; hyaluronate synthase 2; hyaluronic acid synthase 2
Chromosomal Location8q24.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of HAS2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by HAS2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolHAS2
Namehyaluronan synthase 2
Aliases HA synthase 2; hyaluronate synthase 2; hyaluronic acid synthase 2
Chromosomal Location8q24.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of HAS2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolHAS2
Namehyaluronan synthase 2
Aliases HA synthase 2; hyaluronate synthase 2; hyaluronic acid synthase 2
Chromosomal Location8q24.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of HAS2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolHAS2
Namehyaluronan synthase 2
Aliases HA synthase 2; hyaluronate synthase 2; hyaluronic acid synthase 2
Chromosomal Location8q24.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between HAS2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolHAS2
Namehyaluronan synthase 2
Aliases HA synthase 2; hyaluronate synthase 2; hyaluronic acid synthase 2
Chromosomal Location8q24.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting HAS2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.